!!hot!! — Alsscan.24.02.26.molly.little.where.the.sun.shi...

ALS Scan – 24 Feb 2026 – Molly Little – “Where the Sun Shines”

1. The Spark

On February 26, 2024, a thin ribbon of frost clung to the windows of the Neuro‑Imaging Lab at the coastal research institute. Inside, Molly Chen, a 34‑year‑old neurologist‑engineer, was hunched over a laptop, eyes flicking between a cascade of data points and a faded photograph taped to the wall. ALSScan.24.02.26.Molly.Little.Where.The.Sun.Shi...

Months turned into a year, and the scan dates became milestones rather than dread. Molly continued to undergo routine monitoring, each result a data point, each appointment an opportunity to ask questions, to learn, to plan. She cultivated a support network—online forums where people shared their experiences with ALS, local support groups, and a close circle of friends who celebrated her victories, however small. ALS Scan – 24 Feb 2026 – Molly

The words were a relief, a gentle tide that lifted some of the weight from her shoulders. Yet, as Molly lay back on the hospital couch, she felt the paradox of certainty and uncertainty gnaw at her. The scan was clean, but the possibility of a progressive neurodegenerative disease lingered, like a low‑hanging cloud threatening to obscure the sun she loved so much. Months turned into a year, and the scan

Little’s family, armed with the scan’s quantitative data, opted for a clinical trial of a novel antisense oligonucleotide targeting his specific SOD1 mutation. The trial’s primary endpoint was a stabilization of NHI scores for at least six months. At the 6‑month mark, Little’s NHI plateaued at 42 / 100—a modest but meaningful halt to the rapid decline seen in his first year.

Introduction: